演題抄録

臓器別シンポジウム

開催概要
開催回
第58回・2020年・京都
 

進行再発トリプルネガティブ乳癌の最新治療

演題番号 : SY20-4

[筆頭演者]
岩田 広治:1 

1:愛知県がんセンター・乳腺科

 

Triple negative breast cancer (TNBC) is defined as negative of ER, PgR and HER2 status by immunohistochemical evaluation. However, we are recognized that TNBC consist of heterogenous population based on several data of basic and clinical research. Currently, we can use not only chemotherapy regimen but also new action agents based on insurance system for advance and metastatic TNBC. Due to determine treatment strategy, it is important to detect two biomarkers as early line as possible. One is BRCA1/2 mutation in germline, another is PD-L1 status in tumor sample. In BRCA1/2 mutation patients, Olaparib as PARP inhibitor is recommended according to results of OlympiAD trial. In PD-L1 positive patients by immunohistochemical evaluation using SP142 antibody, Atezorizumab as PD-L1 inhibitor with weekly nab-paclitaxel is recommended according to results of Impassion 130 trial. Furthermore, pembrolizumab monotherapy as PD-1 inhibitor is useful drug for metastatic BC with microsatellite instability-high (MSI-H) as a little population.
Several clinical trials using new target drugs have been ongoing for TNBC. AKT inhibitor and HER3 ADC are next candidate drugs for TNBC with specific biomarker. Among this symposium, I would like to present not only standard treatment strategy based on clinical trial data but also design of ongoing trial for future perspective.

前へ戻る